

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-4 (Cancelled)

Claim 5 (Previously Presented) An isolated DNA which codes for the serine protease, as claimed in claim 21.

Claim 6 (Cancelled)

Claim 7 (Previously Presented) An expression vector containing the DNA as claimed in claim 5.)

Claim 8 (Previously Presented) A host cell transformed by the expression vector as claimed in claim 7.)

Claim 9 (Previously Presented) A process for preparing a serine protease comprising culturing a host cell as claimed in claim 8, and recovering the serine protease.


Claims 10-11 (Cancelled)

Claim 12 (Cancelled)

Claim 13 (Cancelled)

Claim 14 (Previously Presented) An isolated DNA which codes for the serine protease domain as claimed in claim 22.

Claim 15 (Previously Presented) An isolated DNA which codes for a kringle domain of a serine protease, as claimed in claim 23.



Claim 16 (Previously Presented) An isolated DNA which codes for a scavenger receptor cysteine-rich domain of a serine protease, as claimed in claim 24.

Claims 17-20 (Cancelled)

~~Polypeptide Claims~~ Claim 21 (Previously Presented) An isolated serine protease consisting of the amino acid sequence indicated in SEQ ID NO: 6.

Claim 22 (Previously Presented) A serine protease domain consisting of an amino acid sequence from amino acid No. 578 to 822 of SEQ ID NO: 6.

Claim 23 (Previously Presented) A kringle domain consisting of an amino acid sequence from amino acid No. 40 to 112 of SEQ ID NO: 6.

Claim 24 (Previously Presented) A scavenger receptor cysteine-rich (SRCR) domain consisting of an amino acid sequence selected from the group consisting of: the amino acid sequence from amino acid No. 117 to 217, from amino acid No. 227 to 327, from amino acid No. 334 to 433, and from amino acid No. 447 to 547 of SEQ ID NO: 6.

Claim 25 (Previously Presented) A process for screening physiologically active substances comprising the steps of measuring the inhibitory or activating activity of a substance using the serine protease as claimed in claim 21, or measuring the binding affinity of a substance to the serine protease as claimed in claim 21.

Claim 26 (Previously Presented) A process for detecting a substance capable of inhibiting or activating the serine protease as claimed in claim 21 comprising contacting a substance with the serine protease, and measuring the activity of the serine protease.

Claims 27-30 (Cancelled)

Claim 31 (Previously Presented) An expression vector containing the DNA as claimed in claim 14.

Claim 32 (Previously Presented) An expression vector containing the DNA as claimed in claim 15.

Claim 33 (Previously Presented) An expression vector containing the DNA as claimed in claim 16.

Claims 34-36 (Cancelled)

Claim 37 (Previously Presented) A host cell transformed by the expression vector as claimed in claim 31.

Claim 38 (Previously Presented) A host cell transformed by the expression vector as claimed in claim 32.

Claim 39 (Previously Presented) A host cell transformed by the expression vector as claimed in claim 33.

Claim 40-43 (Cancelled)

Claim 44 (Previously Presented) A process for preparing a serine protease domain consisting of an amino acid sequence from amino acid No. 578 to 822 of SEQ ID NO: 6 comprising culturing a host cell as claimed in claim 37, and recovering said domain.

Claim 45 (Previously Presented) A process for preparing a kringle domain consisting of an amino acid sequence from amino acid No. 40 to 112 of SEQ ID NO: 6 comprising culturing a host cell as claimed in claim 38, and recovering said domain.

Claim 46 (Previously Presented) A process for preparing a scavenger receptor cysteine-rich domain of a serine protease comprising culturing a host cell as claimed in claim 39, and recovering said domain.

Claims 47-50 (Cancelled)

Claim 51 (Previously Presented) A process for screening physiologically active substances comprising the steps of measuring the inhibitory or activating activity of a substance using the serine protease domain as claimed in claim 22, or measuring the binding affinity of a substance to the serine protease domain as claimed in claim 22.

Claims 52-62 (Cancelled)

Claim 63 (Previously Presented) A process for detecting a substance capable of inhibiting or activating the serine protease as claimed in claim 22 comprising contacting a substance with the serine protease, and measuring the activity of the serine protease.